Incorporating Long-Acting Insulin Glargine Into the UVA/Padova Type 1 Diabetes Simulator for In Silico Testing of MDI Therapies
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Glargine 100 U/mL (Gla-100) and 300 U/mL (Gla-300) are long-acting insulin analogs providing basal insulin supply in multiple daily injection (MDI) therapy of type 1 diabetes (T1D). Both insulins require extensive testing to arrive at the optimal dosing regimen, e.g., timing and amount. Here we aim at a simulation tool for evaluating benefits/risks of different dosing schemes and up-titration rules for both Gla-100 and Gla-300 before clinical testing. METHODS: A new pharmacokinetic (PK) model of both Gla-100 and Gla-300 was incorporated into the FDA-accepted University of Virginia/Padova T1D simulator: Specifically, a joint parameter distribution, built from PK parameter estimates, was used to generate individual PK parametrizations for each in silico subject. A virtual trial comparing Gla-100 vs. Gla-300 was performed and assessed against a clinical study to validate the glargine simulator. RESULTS: Like in vivo, in silico both insulins performed similarly with respect to glucose control: percent time of glucose between [80-140] mg/dL with Gla-100 vs. Gla-300 (primary endpoint) were 41.5 ± 1.1% vs. 39.0 ± 1.2% (P = 0.11) in silico, 31.0 ± 1.6% vs. 31.8 ± 1.5% (P = 0.73) in vivo. CONCLUSIONS: The glargine simulator reproduced the main findings of the clinical trial, proving its validity for testing MDI therapies. SIGNIFICANCE: In silico testing of MDI therapies can help designing clinical trials. Due to the more standardized settings in silico (e.g., standardized meals and strict adherence to titration rule), any potential treatment effect is reaching statistical significance in simulation vs. clinical trial.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“models of acetaminophen pharmacokinetic and long-acting insulin were introduced; [74][75][76]”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [76]
Citations
Cites
Meal Simulation Model of the Glucose-Insulin System
Dalla Man, C., Rizza, R. A., & Cobelli, C. (2007) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2007.893506 · Cited by 955 · cited 2×
“048L/kg) and second we reparameterized the model so that m2 , m3 , m4 become function of m1 , the plasma insulin clearance (CL, L/min) and VI , according to what was done in [10].”
MethodSelf-citationBecker, R. H. A., Dahmen, R., Bergmann, K., Lehmann, A., Jax, T., & Heise, T. (2015) · Diabetes Care · doi:10.2337/dc14-0006 · Cited by 407 · cited 3×
“We refer to [7], [8],”
MethodResultKovatchev, B. P., Cox, D. J., Gonder-Frederick, L. A., Young-Hyman, D., Schlundt, D., & Clarke, W. (1998) · Diabetes Care · doi:10.2337/diacare.21.11.1870 · Cited by 310 · cited 1×
“Gla-100 in terms of percent time in target 70–180 mg/dL (Tt), tight target 80–140 mg/dL, (Ttt), below 70 mg/dL (Tb), above 180 mg/dL (Ta), BG mean (MBG) and standard deviation (SD), low and high BG indexes (LBGI, HBGI) [24], [25], and hourly risk range (HRR) [26].”
BackgroundThe UVA/Padova Type 1 Diabetes Simulator Goes From Single Meal to Single Day
Visentin, R., Campos-Náñez, E., Schiavon, M., Lv, D., Vettoretti, M., Breton, M., Kovatchev, B. P., Dalla Man, C., & Cobelli, C. (2018) · Journal of Diabetes Science and Technology · doi:10.1177/1932296818757747 · Cited by 280
Self-citationMetrics for glycaemic control - from HbA1c to continuous glucose monitoring
Kovatchev, B. P. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.3 · Cited by 272
Carbohydrate counting accuracy and blood glucose variability in adults with type 1 diabetes
Brazeau, A. S., Mircescu, H., Desjardins, K., Leroux, C., Strychar, I., Ekoé, J. M., & Rabasa-Lhoret, R. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.10.024 · Cited by 265 · cited 1×
“, timing and amount, were generated as reported in [14], mimicking the habits occurring in real life: three meals per day were randomly generated for each subject assuming mealtime uniformly distributed in the intervals 06:30 am–08:00 am (breakfast), 11:30 am–01:00 pm (lunch), 06:30 pm–08:00 pm (dinner); meal amounts…”
MethodHome, P. D., Bergenstal, R. M., Bolli, G. B., Ziemen, M., Rojeski, M., Espinasse, M., & Riddle, M. C. (2015) · Diabetes Care · doi:10.2337/dc15-0249 · Cited by 221 · cited 1×
“19 U/kg [23].”
A minimal model of insulin secretion and kinetics to assess hepatic insulin extraction
Toffolo, G., Campioni, M., Basu, R., Rizza, R. A., & Cobelli, C. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00473.2004 · Cited by 142
Self-citationLow within‐ and between‐day variability in exposure to new insulin glargine 300 U/ml
Becker, R. H. A., NOWOTNY, I. K., Teichert, L., Bergmann, K., & Kapitza, C. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12416 · Cited by 133 · cited 1×
“respectively, as reported in [22].”
Toward a Run-to-Run Adaptive Artificial Pancreas: In Silico Results
Toffanin, C., VISENTIN, R., Messori, M., Palma, F. D., Magni, L., & Cobelli, C. (2017) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2017.2652062 · Cited by 123 · cited 1×
“sensitivity [15] and the dawn phenomenon [16], which extended the domain of validity of the simulator from single- to multiplemeal scenarios.”
BackgroundSelf-citation
Cited by
Mehmood, S., Ahmad, I., Arif, H., Ammara, U. E., & Majeed, A. (2020) · Applied System Innovation · doi:10.3390/asi3030031 · Cited by 58
Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility
Cobelli, C., & Kovatchev, B. (2023) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231195081 · Cited by 46
“…extended beyond its initial single-meal realm of application; 73 models of acetaminophen pharmacokinetic and long-acting insulin were introduced; 74-76 the intraperitoneal (IP) absorption of insulin was modeled; 77,78 and replay simulation and insulin sensitivity assessment techniques were…”
MethodSelf-citationVISENTIN, R., Cobelli, C., & Man, C. D. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0110 · Cited by 44
Self-citationMughal, I. S., Patané, L., & Caponetto, R. (2024) · Annual Reviews in Control · doi:10.1016/j.arcontrol.2024.100937 · Cited by 46
Fathi, A. E., Kearney, R. E., Palisaitis, E., Boulet, B., & Haidar, A. (2020) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2020.3023555 · Cited by 25
“Models describing the pharmacokinetics of long-acting insulins exist in the literature [25], [26].”
BackgroundCobelli, C., & Man, C. D. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211015268 · Cited by 24
Self-citationSchiavon, M., VISENTIN, R., Giegerich, C., Sieber, J., Man, C. D., Cobelli, C., & Klabunde, T. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0027 · Cited by 21
“(2) was finally incorporated in the T1DS 17 by equipping each in silico subject with a set of five parameters describing the sc absorption of insulin Deg-100.”
InfluentialSelf-citationCescon, M., Deshpande, S., Nimri, R., Doyle, F. J., & Dassau, E. (2020) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2020.3005622 · Cited by 22
“76 [min], whereas in comparison, in [23], [32], the insulin peak of 22.”
BackgroundResultFathi, A. E., Fabris, C., & Breton, M. D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.795895 · Cited by 19
Estremera, E., Cabrera, A., Beneyto, A., & Vehí, J. (2022) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2022.104141 · Cited by 20
Modeling Subcutaneous Absorption of Long-Acting Insulin Glargine in Type 1 Diabetes
Schiavon, M., VISENTIN, R., Giegerich, C., Klabunde, T., Cobelli, C., & Man, C. D. (2019) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2019.2919250 · Cited by 18
Self-citationLu, X., Cai, D., Liu, W., Ji, L., & Shi, D. (2025) · IEEE Transactions on Automation Science and Engineering · doi:10.1109/tase.2025.3548101 · Cited by 10
“In this way, we use an action model of long-acting basal insulin [41] to obtain its time evolution of acting dosage, which is utilized to replace the input of continuous basal insulin signals for the original IS calculator.”
Tailoring the Padova Type 2 Diabetes Simulator for Treatment Guidance in Target Populations
VISENTIN, R., Schiavon, M., Bonet, J., Riz, M., Wagenhuber, B., & Man, C. D. (2024) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2024.3352153 · Cited by 9
“…[2], [3], [4] that has been accepted and widely used as decision support system for testing several diabetes technology treatments, such as artificial pancreas prototypes (e.g., [5], [6], [7]) and, more recently, glucose monitoring systems and novel insulin formulations (e.g., [8], [9], [10], [11]).”
MethodSelf-citationSun, X., Liu, J., Çınar, A., Yu, X., & Tan, S. (2023) · IEEE Transactions on Control Systems Technology · doi:10.1109/tcst.2023.3291560 · Cited by 10
“The efficiency of the proposed ET-MPC challenged by unannounced meals is evaluated by using a cohort of 30 subjects (ten adolescents, ten adults, and ten children) in the FDA-accepted UVA/Padova simulator [37], [38], [39], [40], TABLE I”
BackgroundMethodModeling Intraperitoneal Insulin Absorption in Patients with Type 1 Diabetes
Schiavon, M., Cobelli, C., & Dalla Man, C. (2021) · Metabolites · doi:10.3390/metabo11090600 · Cited by 6
“The choice was driven by the necessity to keep such a model as simple as possible, to favor both the a priori and the a posteriori identifiability, but also to make the model easy to incorporate in the UVa/Padova T1D Simulator, as done in [26,27].”
MethodSelf-citationVISENTIN, R., Schiavon, M., & Man, C. D. (2020) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc44109.2020.9175271 · Cited by 7
“Only parameter vectors with Mahalanobis distance lower than that corresponding to the 95 th percentile were included in the in silico population, paralleling what was done in [2],[21].”
MethodSelf-citationSirael: Virtual Metabolic Machine
Koutný, T. (2024) · Biomedical Materials & Devices · doi:10.1007/s44174-024-00199-9 · Cited by 3
“For example, reference [8] demonstrates considerable amount of work needed to simulate insulin distribution in plasma with an expert-designed compartment decomposition.”
Yoo, J., Rachim, V. P., Jung, S., & Park, S. (2024) · IEEE Access · doi:10.1109/access.2024.3518832 · Cited by 5
“The simulator was modified to allow both rapid-acting and slow-acting insulin to simulate the bolus and basal, respectively [27].”
Ganji, M., Fathi, A. E., Fabris, C., Lv, D., Kovatchev, B. P., & Breton, M. D. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.109714 · Cited by 6
“The UVA/Padova T1D simulator, a simulation platform accepted by the U.S. Food and Drug Administration (FDA), has been utilized for years as a substitute for animal pre-clinical trials, opening new possibilities for designing personalized treatments[20], [21], [22], [23], [24], [25].”
MethodChen, J., Shi, D., Cai, D., Liu, W., Ji, L., & Shi, L. (2025) · IEEE Transactions on Instrumentation and Measurement · doi:10.1109/tim.2025.3554905 · Cited by 4
“…form : Here Considering the effect of different daily basal boluses on the estimation of IS, we introduce the glargine pharmacokinetics model [31] to smooth the impulsive input, and to compute how many doses of basal insulin are involved at mealtime where B [mU/kg/min] and Ra I ( t )…”
Faggionato, E., Schiavon, M., & Man, C. D. (2021) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc46164.2021.9629554
“Such model will become an important component of in silico platforms, like the UVa/Padova T1D simulator [6] and the Padova T2D simulator [10].”
BackgroundMethodSelf-citationReinforcement Learning Adjustment of Conventional Insulin Therapy for People with Type 1 Diabetes
Serafini, M. C., Fushimi, E., & Garelli, F. (2024) · IEEE Biennial Congress of Argentina (ARGENCON) · doi:10.1109/argencon62399.2024.10735891 · Cited by 2
“The proposal is evaluated in silico using the LAA subsystem presented in [13], [14] incorporated into the UVA/Padova Simulator [15].”
Method
Metadata
- Authors
- Visentin, R., Schiavon, M., Giegerich, C., Klabunde, T., Man, C. D., & Cobelli, C.
- Affiliations
- University of Padua (IT)
- Sanofi (Germany) (DE)
- ORCID
- Venue
- IEEE Transactions on Biomedical Engineering
- Published
- 2019-10
- Volume
- 66
- Issue
- 10
- Pages
- 2889-2896
- ISSN
- 0018-9294 (ISSN-L)
- 1558-2531
- OpenAlex
- W2913964535
- Cited by
- 22
- References
- 25
- Citations by year
- 2025: 3 · 2024: 5 · 2023: 2 · 2022: 2 · 2021: 3 · 2020: 6 · 2019: 1
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- IEEE Transactions on Biomedical Engineering (publishedVersion)
- PubMed (publishedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- long-acting insulin, insulin glargine, type 1 diabetes, UVA/Padova simulator, pharmacokinetic modeling, insulin dosing regimens, glycemic control
- MeSH terms
- Insulin Glargine, Blood Glucose, Computer Simulation, Diabetes Mellitus, Type 1, Drug Administration Schedule, Humans, Hypoglycemic Agents, Injections, Insulin, Long-Acting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.